BioVenture View is an authoritative newsletter keeping readers informed of research and business developments in the global biotechnology industry. A team of highly respected international correspondents maintain the broadest coverage and analysis of events worldwide providing accurate, reliable and timely analysis of the biotech developments.
BioVenture View (BVVIEW, BVVC, and BVVD) is a subset of the Pharmaceutical and Healthcare Industry News (PHIN, PHIC, and PHID), also available on Ovid Gateway.
The following alphabetical list provides the two-letter label, the relevant alias, and an example for each BioVenture View database field.
Note: The fields below do not have Indexing (word or phrase) listed because Index browsing is not available in this database.
===== ============ Label Name/Example ===== ============ an Accession Number "00812036".an. The Accession Number field (AN) contains a unique sequential ight-digit number assigned to each document. ba Article Type multi paragraph article.ba. The Article Type (BA) field contains one of two values, multi-paragraph article or single paragraph article. pd Publication Date "20030812".pd. The Publication Date (PD) field contains the date the article was sent. The format is YYYYMMDD. sf Special Features table.sf. The Special Features (SF) field contains any special attributes for that article. so Source bioventure.so. The Source (SO) field contains the full name of the authoring publication. If the article did not make it to print publication, the words "Online-plus" are put after the authoring publication's name. ti Title partnership.ti. antibiotics.ti. The Title (TI) field contains the title of the record. Common words such as a, an, the, etc. are not indexed. tx Text autoimmune.tx. and colloral.tx. lilly.tx adj10 fluoxetine.tx. The Text (TX) field contains the text of the article. up Update Code "200338".up. 20032$.up. The Update (UP) field contains the year and week the data was sent to the vendor. This field can be used to find the newest data. The format is YYYYWW, where Y is year and W is week.
| a | by | having | neither | seem | those |
| about | can | how | no | seen | through |
| after | could | however | nor | several | thus |
| again | did | if | not | should | to |
| all | do | in | obtain | show | under |
| almost | does | into | obtained | showed | up |
| also | done | is | of | shown | upon |
| although | during | it | often | shows | use |
| always | each | its | on | significant | used |
| among | either | itself | only | significantly | using |
| an | enough | just | or | since | various |
| and | especially | kg | other | so | very |
| another | etc | km | our | some | was |
| any | followed | largely | out | such | we |
| approximately | following | like | overall | suggest | were |
| are | for | made | per | than | what |
| as | found | mainly | perhaps | that | when |
| at | from | make | possible | the | whereas |
| be | further | may | previously | their | which |
| because | give | might | quite | theirs | while |
| been | given | min | rather | them | with |
| before | giving | mm | really | then | within |
| being | had | most | regarding | there | would |
| between | hardly | mostly | resulted | these | |
| both | has | must | resulting | they | |
| but | have | nearly | same | this |
The following limits are available from the Limit menu or the Search Fields on the Main Search Page:
Latest Update
Sentence Syntax: limit 1 to latest update
limit 1 to up=200317
Command Syntax: ..l/2 up=200317
Publication
Sentence Syntax: limit 1 to "bioventure view: international
business and research developments in biotechnology"
Tables
Sentence Syntax: limit 1 to tables
Citation 1 Copyright 2000 PJB Publications Ltd. - All Rights Reserved. Accession Number 00808292 Source Bioventure-View - International Business and Research Developments in Biotechnology 1814 p11. Title Less cash leads to new spin-off. Article Type Multi Paragraph Article. Text PamGene International BV 's-Hertogenbosch, The Netherlands To support the final development costs and early 2004 market launch of its microarray PamStation 96, Dutch biotech PamGene has completed a series B round of euro10.0M. The company claims the automated system, in combination with validated biomarkers, will provide a more 'complete solution' to drug discovery. Dr Bas Hulshof, marketing manager for PamGene, told BVV: "It was a very tough time for fundraising, so we are happy to close the round. We set out to bring in more, but in the current climate, it just wasn't possible." Because of this, the company has made two significant changes to its business plan. "We have spun-off a company called Check-Points (Wageningen, The Netherlands), for the detection and identification of a range of micro-organisms for quality testing in food, water and fermentation processes," he revealed. PamGene has also extended rights to Olympus Optical (Tokyo, Japan) to market its low-through! put flow-through microarray system. Since partnering in 2001, Olympus has paid PamGene approximately euro6.0M. Commenting on PamStation 96, Hulshof said: "Traditional microarrays use a hard surface, such as glass, but we use a porous substrate that increases the reaction surface by about 500 times... These differences significantly increase chemical interactions and make analysis faster - results can be generated in 5-30 minutes. Traditional microarrays generally operate overnight." While PamGene's system has competition from other traditional microarray suppliers such as US-based Affymetrix and UK-based Amersham, Hulshof believes its microarray is the next generation. "Affymetrix' technology is used to analyse a whole genome using thousands of spots, while ours tests the limited number of spots that are of interest - making it faster. Our system can also perform a wider variety of tests, real-time detection and temperature variation, enabling us to generate more useful data! , providing a more comprehensive solution to drug discovery."! The financing will also help fund the development of the company's range of biomarkers for specialist toxicology and ADME assays. "We have nearly completed our liver and kidney gene sets, which will be ready for market later this year and we have plans for further gene sets," he concluded. The round was led by a euro2.5M investment by LCF Rothschild Venture Partners, and existing investors GIMV, Alta Partners and Life Sciences Partners. BIOVENTURE VIEW FILED 11 July 2003 COPYRIGHT 2003 PJB Publications Ltd Publication Date 20030715 Update Code 200333 Citation 2 *Copyright 2003 PJB Publications Ltd. - All Rights Reserved.* Accession Number 00808294 Source Bioventure-View - International Business and Research Developments in Biotechnology 1814 p17. Title Islet implants successful in primate studies. Title Islet implants successful in primate studies. Article Type Multi Paragraph Article. Text Novocell Inc Irvine, CA Novocell has reported promising results from a pilot study of encapsulated islet cell implants in diabetic primates. In the first pilot series five monkeys were implanted, and in the second series, four baboons. All the animals were standard models of diabetes, requiring daily insulin injections before the implantation. After implantation, three monkeys and one baboon no longer required insulin injections for up to 10 months. "At this point the animals were sacrificed, this was the end of the trial," Paul Latta, CEO of Novocell, told BVV. The two other monkeys and three baboons were able to achieve significantly reduced blood glucose levels with reduced insulin injections. Each animal received islet cells from donors of the same species, and the cells were encapsulated with Novocell's proprietary polyethylene glycol (PEG) conformal coating technology to protect the cells from destruction by the recipient's immune system. "This is the crux of the technology. Islet transplantation isn't being done commercially by anyone else. This is firstly because of the need for full immunosuppressive therapy, which isn't desirable, and secondly because of the limited number of donor cells available. Our PEG technology reduces the need for immunosuppressants, and we're developing new and improved ways of isolating the islet cells," Latta explained. All the animals received the implanted islet cells under the skin of the abdomen in a "simple" procedure requiring local anaesthetic. "The cells just stay right there, they have a ready blood supply providing glucose and nutrients and they're happy." The animals received low dose cyclosporine for 30 days from the time of the implant. All the animals had living islet cells when the implants were removed for examination after 10 months. "Although these are preliminary studies, we learned several very important things," commented Dr David Scharp, CSO of Novocell. "First, our PEG encapsulation ! system protected implanted cells from immune destruction long! term in multiple primates. Second, the islets were able to live and function subcutaneously, implanted just under the skin. Third, HbA1c, the long term measurement of blood glucose values, was nearly normalised in the successfully implanted baboons, both those that achieved insulin independence and those that had significant function with a reduced insulin requirement. Fourth, just as is the experience with human islet implants under full immunosuppression, the quantity and quality of the islets implanted in each animal determined whether or not the animal was able to become completely insulin injection free." "It was similar to a dose-dependent response," said Latta. "The next step is to conduct more definitive studies on a larger number of animals to confirm these preliminary findings and implement further improvements that we have planned. These include improvements to the encapsulation system and, most importantly, better isolation of the islet cells. The FDA has stated that we! need to conduct a trial with 30 animals before we can move into human studies." BIOVENTURE VIEW FILED 11 July 2003 COPYRIGHT 2003 PJB Publications Ltd Publication Date 20030715 Update Code 200333
Copyright PJB Publications Ltd 2004: All rights reserved.
The following is allowed without permission or charge:
Uses other than those described above require a license agreement between customer and PJB Publications Ltd.
Field Guide Updated May 26, 2005